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How it all began...
• A NASA engineer received a heart transplant performed by Drs.
DeBakey and Noon after suffering a serious heart attack
• 6 months later that engineer returned to work at NASA determined
to use space technology to help people with heart disease
• A relationship between NASA and Drs. DeBakey and Noon was
formed and the group worked to develop a low cost, low power
implantable ventricular assist device (VAD)
The Tale of Technolo T
• NASA patented the method to reduce pumping damage
to red blood cells and the design of a continuous flow
heart pump (#s,678,306 and #5,947,892)
• The technology and methodology were licensed
exclusively to MicroMed Technology, Inc
• In late 1998 MicroMed received international quality and
electronic certifications and began clinical trials in Europe
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Devices
• Ventricular assist devices
were developed to bridge
the gap between heart
failure and transplant
• Early devices were
cumbersome, damaged
red blood cells, and
increased the risk of
developing dangerous
blood clots
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How did NASA technology and
analysis impact the evolution of
the VAD?
From Rocket Fuel to Blood ^^.
• Application emerged from NASA turbopump technology and
computational fluid dynamics analysis capabilities
• To develop the high performance required of the Space Shuttle
main engines, NASA pushed the state of the art in the technology of
turbopump design
• NASA supercomputers and computational fluid dynamics software
developed for se-nth modeling an 	 f fuel and oxidizer
flow thr	 ocket engines was used in the mini 	 tion and
opti z ion of a very small heart pump
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• The original ventricular assist
device, top, and the after
modifications by NASA,
center and bottom
Adding an inducer to the
MicroMed DeBakey VAD°
eliminates dangerous back
flow by increasing pressure
and making flow more
continuous
The device is subjected to the
highest pressure around the
blade tips, shown in magenta
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A Bridge or a Destination 	 A,
• Approximately 5 million people worldwide suffer from chronic heart
failure at a cost of 40 billion dollars
• In the US, more than 5000 people are on the transplant list and less
than 3000 transplants are performed each year due to the lack of
donors
• The success of ventricular assist devices has led to an application as a
therapeutic destination as well as a bridge to transplant
• This success has been attributed to smaller size, improved efficiency,
and reduced complications such as the formation of blood clots and
MicroMed VAD
• Adult and Pediatric HeartAssist 5 Device is approved for
clinical use in the European Union
• Pediatric HeartAssist 5 is FDA approved
• Over 440 implants worldwide accounting for more than
130 patient years of life
• Clinical testing is underway in the US on the Adult
HeartAssist 5
The Future of the VAD
• Transcutaneous induction to power the device
rather than percutaneous cables = reduced
risk of infection and more patient freedom
• NIH funding MicroMed for the development
of an artificial heart through the use of both a
left and right ventricular assist device
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